Reply to: 'Comment on Kridin et al.-Considering both relative and absolute risk differences in infection risk between biologics classes in patients with psoriasis'.

Kridin, Khalaf; Zirpel, Henner; Mruwat, Noor; Ludwig, Ralf J; Thaci, Diamant

Reply to: 'Comment on Kridin et al.-Considering both relative and absolute risk differences in infection risk between biologics classes in patients with psoriasis'.

Kridin, Khalaf; Zirpel, Henner; Mruwat, Noor; Ludwig, Ralf J; Thaci, Diamant.

Afiliação

Kridin K; Lubeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
Zirpel H; Unit of Dermatology and Skin Research Laboratory, Galilee Medical Center, Nahariya, Israel.
Mruwat N; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Ludwig RJ; Comprehensive Center for Inflammation Medicine, University-Hospital Schleswig-Holstein, Lübeck, Germany.
Thaci D; Unit of Dermatology and Skin Research Laboratory, Galilee Medical Center, Nahariya, Israel.

J Eur Acad Dermatol Venereol ; 38(4): e354-e355, 2024 Apr.

Article em En | MEDLINE | ID: mdl-37909324

Assuntos

Produtos Biológicos; Psoríase; Humanos; Produtos Biológicos/efeitos adversos; Psoríase/tratamento farmacológico; Psoríase/induzido quimicamente; Suscetibilidade a Doenças/induzido quimicamente

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Produtos Biológicos Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Produtos Biológicos Idioma: En Ano de publicação: 2024 Tipo de documento: Article